Thermo Fisher Scientific Inc., the world leader in serving science has introduced the ToxInsight DILI Assay Cartridge, a groundbreaking new tool for assessing the liver toxicity risk of chemical compounds. It will help pharmaceutical companies improve their productivity by better assessing liver toxicity early in the drug development process, specifically reducing the risk of drug-induced liver injury (DILI) – the primary reason for post-market drug withdrawal. Designed to be used with the Thermo Scientific ToxInsight IVT image cytometry platform, the ToxInsight DILI Assay Cartridge identifies drug induced hepatotoxicity by simultaneous detection of multiplexed toxicity biomarkers in single cells. It includes all the reagents, assay protocols, analysis and data reporting capabilities to profile compounds for hepatotoxicity with high sensitivity and specificity. The cartridge has been extensively validated with a known hepatotoxic compound “truth-set” on a range of hepatic cell-lines, including rat and human primary hepatocytes.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
- Advertisement -
Latest stories
Related stories
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
